HELP Therapeutics and China Resources Sanjiu Join Forces to Advance Cell Therapy for Heart Failure

HELP Therapeutics and China Resources Sanjiu’s Partnership

Image Credits: Biopharma APAC

Announcement

HELP Therapeutics, a regenerative medicine leader, and China’s largest China Resources Sanjiu Pharmaceutical company have partnered to commercialize and co-develop the investigational cell therapy HiCM-188. This strategic partnership will expand engagement and contribute to the healthcare market.

Concern

Heart failure needs major medical treatment to be focused on. China’s 12 million adults are suffering from heart failure addition to 2.97 million new cases each year has been recorded. The five-year survival rate is equal to many malignant tumors. Heart transplantation is an effective treatment for end-stage patients. The challenge is that fewer than 1000 patients receive a matching heart donor on time. Cell therapy is a trusted alternative and a transitional change towards healthcare for the increased patient population. The alternatives to severe health diseases are an effective change in therapy and the healthcare market.

Solution

HiCM-188 is the first ever iPSC-derived regenerative therapy for heart failure. This therapy has received an IND clearance from the United States and China. Currently, the candidates are in phase 1 and 2 trials in the US and phase 2 clinical trials in China. In Thailand and Singapore, HiCM-188 showed efficacy and strong safety for more than five years with its long-term follow-up.

Views and Statements

Founder and CEO of HELP Therapeutics, Dr. Wang Jiaxian said, “The co-development agreement with china resources sanjiu is a milestone for HELP Therapeutics. Their commercialization, innovation, and clinical network will leverage the availability of our therapies for patients and largely support the growth of China’s cell therapy industry.”

Chairman of China Resources Sanjiu, Mr. Qiu Huawei, said, “Cell therapy is the future of life sciences that provides a potential treatment for refractory and aging-related diseases. Through the company’s subsidiary, Tasly Pharmaceuticals, we have improved the MSC cell therapy. The partnership with HELP Therapeutics will strengthen our company’s commitment to cell therapy innovation. HELP’s popular Ipsc platform and enhanced clinical pipeline prove them as an ideal partner. We will, together will give new hope to heart failure patients.”

Academician of the Chinese Academy of Sciences, Professor Junbo Ge, described this collaboration as a milestone in China’s cell and gene therapy landscape. Additionally, he noted, “HELP Therapeutics is popularly known for addressing complex clinical needs in heart failure and acts as a bridge to myocardial repair and heart transplantation. Further, this partnership is capable of redesigning treatment paradigms for patients globally.”